Technologies

A series of compounds derived from 2-aminotetralin and piperazine fragments have been synthesized, which exhibit high CNS activity in vivo and in vitro. Some of the selected lead compounds have exhibited potent in vivo activity in a Parkinson?s disease animal model with long extended duration of action. In particular, these compounds show high D3 receptor affinity and/or high D3/D2 selectivity. In addition to the potential therapeutic treatment of Parkinson?s disease and depression, these novel compounds have possible application in the treatment of a number of other neurological disorders such as cocaine addiction, restless leg syndrome or as an atypical antipsychotic agent.